NASDAQ:ACIU AC Immune Q2 2025 Earnings Report $2.43 +0.05 (+2.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 09/12/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast AC Immune EPS ResultsActual EPS-$0.25Consensus EPS -$0.20Beat/MissMissed by -$0.05One Year Ago EPSN/AAC Immune Revenue ResultsActual Revenue$1.65 millionExpected Revenue$1.98 millionBeat/MissMissed by -$333.00 thousandYoY Revenue GrowthN/AAC Immune Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time12:00AM ETUpcoming EarningsAC Immune's Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled on Friday, October 31, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) AC Immune Earnings HeadlinesLeerink Partners Reaffirms Their Buy Rating on AC Immune SA (ACIU)3 hours ago | theglobeandmail.comAC Immune (NASDAQ:ACIU) Earns Buy Rating from BTIG ResearchSeptember 10, 2025 | americanbankingnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 14 at 2:00 AM | American Alternative (Ad)AC Immune SA: Strategic Focus and Innovative Platforms Drive Buy Rating Amid Promising Immunotherapy DevelopmentsSeptember 8, 2025 | tipranks.comAC Immune SA Announces Strategic Focus and Workforce ReductionSeptember 4, 2025 | tipranks.comAC Immune SA: AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash RunwaySeptember 4, 2025 | finanznachrichten.deSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates. Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. Its SupraAntigen™ platform is designed to generate active vaccines that elicit a targeted immune response against disease-associated proteins, while its Morphomer™ platform discovers small molecules that bind misfolded proteins and inhibit their toxic aggregation. Among the company’s leading assets are anti-tau vaccine candidates in mid-stage clinical trials and small-molecule inhibitors aimed at disrupting toxic oligomer formation. AC Immune maintains collaborations and strategic partnerships with major pharmaceutical firms to accelerate development and expand global reach. Notable alliances include research agreements with Janssen Pharmaceuticals and UCB to co-develop immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as partnerships with Eli Lilly and Genentech focused on diagnostic imaging agents. These collaborations strengthen AC Immune’s ability to advance its pipeline while accessing broader regulatory and commercialization expertise. Under the leadership of CEO Dr. Andrea Pfeifer, who co-founded the company and has guided its growth since inception, AC Immune continues to invest in innovative approaches to neurodegeneration. The company’s integrated research and development model, combining both therapeutic and diagnostic strategies, aims to deliver precision solutions that address unmet medical needs in aging populations across North America, Europe and Asia.View AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are Done Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
